- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07825896
Autogenous Sticky Bone Plus Platelet-rich Fibrin Membrane Versus Xenograft With Collagen Membrane for Posterior Atrophic Mandible
September 13, 2026 updated by: Alexandria University
Autogenous Sticky Bone Plus Platelet-rich Fibrin Membrane Versus Xenograft With Collagen Membrane for Treatment of Posterior Atrophic Mandible (A Randomized Controlled Clinical Trial)
Background: Teeth loss in the posterior mandible initiates residual ridge resorption, this causes difficulty in implant placement so ridge augmentation must be done either simultaneous with implant placement or in a staged approach Aim: To evaluate the effect of autogenous sticky bone with PRF membrane and xenograft with collagen membrane with simultaneous implant placement clinically on primary and secondary implant stability, and radiographically on bucco-lingual width gain, bone density and crestal bone loss
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mohamed Essam, BDS
- Phone Number: 01225710437
- Email: mohamedessam2363@gmail.com
Study Locations
-
-
Azarita
-
Alexandria, Azarita, Egypt, 00203
- Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with missing posterior mandibular teeth.
- Horizontal bone defect with width < 5.5 mm.
- Adequate zone of keratinized tissue
Exclusion Criteria:
- Presence of infection or periapical lesions in adjacent teeth.
- Medically compromised patients with a condition that affects the procedure.
- Insufficient inter-arch distance.
- Bruxism or clenching.
- Alcoholism.
- Heavy Smokers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control Group
|
Patients in this group will be treated using a xenograft with a collagen membrane.
|
|
Experimental: Test Group
|
Patients in this group will be treated using autogenous sticky bone with PRF membrane.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in implant stability
Time Frame: up to 6 months
|
Implant stability will be recorded immediately after placement (1ry stability) and after 6 months (2ry stability ) by using osstell device.
The result is presented in form of ISQ value from 1 to 100, the higher the ISQ the higher the stability of implant
|
up to 6 months
|
|
change in bucco-lingual bone thickness
Time Frame: up to 6 months
|
All participants in the study will be advised to undergo CBCT before implant placement to measure bucco-lingual bone thickness, and again 7 days postoperatively and 6 months after implant placement to assess the following.
|
up to 6 months
|
|
change in marginal bone level
Time Frame: up to 9 months
|
At buccal, lingual, mesial, and distal sites will be evaluated radiographically from the shoulder of the implant to the alveolar crest.
The mean marginal bone loss after the placement of implants will be calculated by subtracting baseline value from the values obtained at 6 and 9 months post implant placement
|
up to 9 months
|
|
change in ridge width
Time Frame: up to 6 months
|
Will be measured immediately and after 6 months, bone width will be measured for each implant at three levels (2, 5, and 10 mm from the alveolar crest) and the mean will be calculated for each implant at each time interval.
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in pain scores
Time Frame: up to 7 days
|
Pain will be assessed for 7 days postoperatively using 10-point visual analouge scale (VAS).
(0-1=None, 2-4=mild, 5-7=moderate, 8-10=severe ).
|
up to 7 days
|
|
change in edema scores
Time Frame: up to 7 days
|
Edema will be assessed by a descriptive 4-point scale immediately post-operative, and at the 2nd,3rd,7th days postoperatively.
Measured as follows: No inflammation = none.
Intra oral swelling confined to the surgical field = mild.
Extra oral swelling in the surgical zone =moderate.
Extra oral swelling spreading beyond the surgical zone =intense.
|
up to 7 days
|
|
change in bone density
Time Frame: up to 6 months
|
Will be measured at 6 points around the implant and a mean value will be calculated
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 25, 2026
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
June 30, 2027
Study Registration Dates
First Submitted
September 13, 2026
First Submitted That Met QC Criteria
September 13, 2026
First Posted (Actual)
September 17, 2026
Study Record Updates
Last Update Posted (Actual)
September 17, 2026
Last Update Submitted That Met QC Criteria
September 13, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1368-07/2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.